Mirvaso (Galderma Laboratories, L.P.)
Welcome to the PulseAid listing for the Mirvaso drug offered from Galderma Laboratories, L.P.. This Adrenergic alpha-Agonists [MoA],alpha-Adrenergic Agonist [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Galderma Laboratories, L.P. |
NON-PROPRIETARY NAME: | brimonidine tartrate |
SUBSTANCE NAME: | BRIMONIDINE TARTRATE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Adrenergic alpha-Agonists [MoA],alpha-Adrenergic Agonist [EPC] |
ROUTE: | TOPICAL |
DOSAGE FORM: | GEL |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2013-08-23 |
END MARKETING DATE: | 0000-00-00 |
Mirvaso HUMAN PRESCRIPTION DRUG Details:
Item Description | Mirvaso from Galderma Laboratories, L.P. |
LABELER NAME: | Galderma Laboratories, L.P. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 5(mg/g) |
START MARKETING DATE: | 2013-08-23 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0299-5980_2c78b1f4-5ebf-4e6f-8b3d-c4d2dc6546e2 |
PRODUCT NDC: | 0299-5980 |
APPLICATION NUMBER: | NDA204708 |
Other BRIMONIDINE TARTRATE Pharmaceutical Manufacturers / Labelers: